Brokerages expect Iterum Therapeutics PLC (NASDAQ:ITRM) to report earnings per share of ($1.96) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Iterum Therapeutics’ earnings. The company is expected to issue its next earnings results on Tuesday, November 13th.

According to Zacks, analysts expect that Iterum Therapeutics will report full year earnings of ($9.68) per share for the current fiscal year, with EPS estimates ranging from ($11.30) to ($8.05). For the next financial year, analysts forecast that the business will post earnings of ($6.41) per share, with EPS estimates ranging from ($7.30) to ($5.52). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Iterum Therapeutics.

Iterum Therapeutics (NASDAQ:ITRM) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($2.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by ($0.78). The business had revenue of $0.19 million for the quarter.

Several analysts have commented on ITRM shares. Zacks Investment Research lowered shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 9th. Needham & Company LLC set a $20.00 price objective on shares of Iterum Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 14th. Finally, Gabelli reaffirmed a “buy” rating on shares of Iterum Therapeutics in a research report on Monday, October 22nd. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $20.75.

In related news, Director Mark Chin acquired 58,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 30th. The stock was purchased at an average cost of $6.10 per share, with a total value of $353,800.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders purchased a total of 62,000 shares of company stock valued at $391,480 over the last ninety days.

Several institutional investors have recently made changes to their positions in ITRM. Glen Harbor Capital Management LLC acquired a new position in Iterum Therapeutics in the 2nd quarter worth approximately $318,000. Dean Capital Investments Management LLC acquired a new position in Iterum Therapeutics in the 2nd quarter worth approximately $406,000. Tyers Asset Management LLC acquired a new position in Iterum Therapeutics in the 2nd quarter worth approximately $437,000. Flinton Capital Management LLC acquired a new position in Iterum Therapeutics in the 2nd quarter worth approximately $556,000. Finally, Neuburgh Advisers LLC acquired a new position in Iterum Therapeutics in the 2nd quarter worth approximately $675,000. 47.63% of the stock is owned by hedge funds and other institutional investors.

ITRM stock opened at $5.93 on Friday. Iterum Therapeutics has a one year low of $5.55 and a one year high of $13.00. The company has a current ratio of 11.53, a quick ratio of 11.53 and a debt-to-equity ratio of 0.12.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Recommended Story: What is Compound Interest?

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.